Harmony Biosciences Holdings (HRMY) Equity Average (2019 - 2026)

Harmony Biosciences Holdings has disclosed Equity Average across 8 years of filings, most recently posting $890.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $890.3 million, up 29.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $890.3 million (up 29.06% YoY), and the FY2025 annual result was $764.7 million, up 35.81% from the prior year.
• Equity Average came in at $890.3 million for Q1 2026 at Harmony Biosciences Holdings, up from $852.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $890.3 million in Q1 2026 to a low of $200.5 million in Q1 2022.
• The 5-year median for Equity Average is $491.2 million (2024), against an average of $537.7 million.
• Across the five-year window, Equity Average jumped 120.58% in 2022 and advanced 13.55% in 2024, its largest moves.
• Harmony Biosciences Holdings' Equity Average stood at $373.4 million in 2022, then climbed by 27.0% to $474.2 million in 2023, then jumped by 32.44% to $628.0 million in 2024, then surged by 35.78% to $852.7 million in 2025, then advanced by 4.41% to $890.3 million in 2026.
• The last three Equity Average figures came in at $890.3 million (Q1 2026), $852.7 million (Q4 2025), and $804.1 million (Q3 2025), per Business Quant data.